Breaking News

  • 11 hours ago

  • Pharma Now Editorial Team

Sanofi's Nuvaxovid Shows Lower Reactogenicity Than mRNA Rival in Phase 4 Trial
Breaking News

More News

Bispecific PD-1xVEGF Data in NSCLC Raises Scale-Up Questions for Merck

Bispecific PD-1xVEGF Data in NSCLC Raises Scale-Up Questions for Merck

Pharma Now Editorial Team

Oral Biologics Push Forces Rethink of Formulation and Manufacturing

Oral Biologics Push Forces Rethink of Formulation and Manufacturing

Pharma Now Editorial Team

Nasal Epinephrine Approval Signals GMP Shifts for Delivery Reformulations

Nasal Epinephrine Approval Signals GMP Shifts for Delivery Reformulati...

Pharma Now Editorial Team

Xilio's Masked T Cell Engager Data Signal New Approach to Solid Tumor Toxicity

Xilio's Masked T Cell Engager Data Signal New Approach to Solid Tumor ...

Pharma Now Editorial Team

Ad
Advertisement

Interviews & Opinions

Article

Five Pillars Of Leadership That Built A Pharma Veteran: Shyam Khante’s 45-Year Pharma Journey

A gold medalist who swept floors, rejected an IIT-equivalent seat, and reached Technical Director at GSK by 34 — Mr. Shyam Khante's five leadership pi...

FT - Mr. Shyam Khante

Read More

Article
“Quality is Driven by Science” – Leadership Lessons from Zydus President Vikram Shukla

FT - Mr. Vikram Shukla

Article
Mr. Patrick Nieuwenhuizen on Contamination Control, AI, and Leadership

FT - Mr. Patrick Nieuwenhuizen

Article
Mr. Laxmikant Tiwari On Compliance, Quality, And Shop-Floor Ops

FT - Mr. Laxmikant Tiwari

Ad
Advertisement
Ad